Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

EPH Receptor A2 Antikörper

Der Maus Monoklonal Anti-EPH Receptor A2-Antikörper wurde für WB, ELISA und IHC validiert. Er ist geeignet, EPH Receptor A2 in Proben von Human zu detektieren. Es sind 2+ Publikationen verfügbar.
Produktnummer ABIN1724651

Kurzübersicht für EPH Receptor A2 Antikörper (ABIN1724651)

Target

Alle EPH Receptor A2 (EPHA2) Antikörper anzeigen
EPH Receptor A2 (EPHA2)

Reaktivität

  • 107
  • 72
  • 47
  • 14
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
Human

Wirt

  • 112
  • 18
  • 4
  • 2
Maus

Klonalität

  • 108
  • 27
  • 1
Monoklonal

Konjugat

  • 71
  • 9
  • 8
  • 7
  • 7
  • 6
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser EPH Receptor A2 Antikörper ist unkonjugiert

Applikation

  • 114
  • 66
  • 27
  • 27
  • 15
  • 14
  • 12
  • 9
  • 7
  • 7
  • 7
  • 4
  • 3
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Klon

1B3C7
  • Verwendungszweck

    EphA2 Antibody

    Aufreinigung

    Ascitic fluid

    Immunogen

    Purified recombinant fragment of EphA2 expressed in E. Coli.

    Isotyp

    IgM
  • Applikationshinweise

    ELISA: 1/10000

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Buffer

    Ascitic fluid containing 0.03 % sodium azide.

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    4 °C,-20 °C

    Informationen zur Lagerung

    Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
  • Abraham, Knapp, Cheng, Snyder, Mittal, Bangari, Kinch, Wu, Dhariwal, Mohammed: "Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 2, pp. 353-60, (2006) (PubMed).

    Landen, Kinch, Sood: "EphA2 as a target for ovarian cancer therapy." in: Expert opinion on therapeutic targets, Vol. 9, Issue 6, pp. 1179-87, (2005) (PubMed).

  • Target

    EPH Receptor A2 (EPHA2)

    Andere Bezeichnung

    EphA2

    Hintergrund

    EPH receptor A2 (EphA2), with 976-amino acid protein (about 107 kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4 and EphB6 are Eph family receptors for Ephrin family ligands. In normal cells, EphA2 negatively regulates cell growth and invasiveness. EphA2 is overexpressed by many human cancers, and is often associated with poor prognostic features. The clinical significance of the expression of EphA2 was observed in breast, prostate, colon, skin, cervical, ovarian, and lung cancers.EphA2 may serve as a novel target for bladder cancer, colonic adenocarcinoma and ovarian cancer therapy.

    Gen-ID

    1969

    UniProt

    P29317

    Pathways

    RTK Signalweg
Sie sind hier:
Chat with us!